Geron (GERN) Corporate presentation summary

Strategic vision and financial guidance

• Aims to build a leading hematology company by maximizing the value of RYTELO, a first-in-class telomerase inhibitor, and maintaining financial discipline with 2026 operating expenses guided at $230M–$240M and expected net product revenue of $220M–$240M.

• Plans to communicate EU commercial strategy for RYTELO by end of 2026 and leverage the balance sheet for innovation.

RYTELO clinical profile and market positioning

• RYTELO is approved in the U.S. and EU for lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia, offering a unique mechanism targeting telomerase.

• Demonstrates higher and durable transfusion independence (39.8% ≥8-week TI vs 15% placebo, median response 52 weeks) and manageable safety profile.

• NCCN guidelines recommend imetelstat as a preferred second-line and first-line option for specific LR-MDS patients.

Clinical data and efficacy

• Phase 3 IMerge trial showed median transfusion independence duration of 51.6 weeks for RYTELO vs 13.3 weeks for placebo.

• Early cytopenias are associated with clinical response and are generally manageable, supporting on-target activity.

• Long-term follow-up suggests no increased risk of death and similar AML progression compared to placebo.